Published on 21/12/2025
Understanding Data Retention Periods by Regulatory Region
Clinical trials generate vast volumes of essential data that must be archived to ensure Good Clinical Practice (GCP) compliance, product approval support, and inspection readiness. Retaining clinical trial records is a legal and ethical obligation that varies by regulatory region. Each authority—whether it’s the USFDA, EMA, CDSCO, or others—mandates specific data retention timelines to ensure integrity and traceability of trial information.
This guide outlines data retention periods across key regulatory jurisdictions, providing pharma professionals and clinical teams with the knowledge needed to implement compliant archiving policies across global studies.
Why Data Retention Matters in Clinical Trials:
Clinical data retention ensures that information generated during the conduct of a study is preserved for:
- 🔍 Regulatory audits and inspections
- 📊 Reanalysis or additional submissions
- 📁 Pharmacovigilance and post-marketing surveillance
- ⚖️ Legal or compliance inquiries
Failure to retain essential documents can compromise marketing applications, lead to inspection findings, and damage sponsor credibility.
Key Documents Subject to Retention:
Essential documents required under ICH GCP and local regulations include:
- Trial Master File (TMF)
- Case Report Forms (CRFs)
- Informed Consent Forms (ICFs)
- Monitoring visit reports
- Statistical analysis plans and datasets
- Audit trails and metadata from EDC systems
These must be retained in an
Global Overview of Retention Periods:
| Region | Regulatory Body | Minimum Retention Period |
|---|---|---|
| United States | FDA (21 CFR 312.57) | 2 years after approval or discontinuation |
| European Union | EMA (EU Regulation No. 536/2014) | 25 years post-trial |
| India | CDSCO | 5 years after trial completion or marketing approval |
| Canada | Health Canada | 25 years (Guidance GCP-003) |
| Australia | TGA | 15 years (Therapeutic Goods Regulations 1990) |
| Brazil | ANVISA | 15 years minimum |
| South Africa | SAHPRA (MCC) | 15 years minimum |
| China | SFDA (NMPA) | 10 years minimum |
| ICH GCP | International | 2 years after last approval and discontinuation |
Document Retention for Sponsors and Sites:
✔ Sponsor Responsibilities:
- Ensure trial master file (TMF) is complete and archived securely
- Document all trial-level correspondence and final reports
- Preserve electronic records, including audit trails and metadata
- Define retention plans in SOPs and contracts with vendors/CROs
✔ Investigator Site Responsibilities:
- Retain site-specific ICFs, logs, CRFs, and source documents
- Ensure readability and traceability of all patient records
- Document storage location, access logs, and retention periods
- Comply with local GCP and ethics committee retention policies
Use Pharma SOP templates to establish clear responsibilities and retention frameworks for both sponsor and investigator sites.
Physical vs Electronic Record Retention:
Retention timelines apply regardless of storage format:
- Physical Records: Must be stored in access-controlled, environmentally secure facilities with documented logs
- Electronic Records: Must comply with 21 CFR Part 11, EU Annex 11, and validated pharma validation protocols
eTMF systems must maintain metadata, audit trails, user access logs, and long-term format compatibility (PDF/A, XML, etc.)
Best Practices for Multi-Region Trials:
- 📝 Align your retention period with the strictest applicable regional regulation
- 📍 Centralize retention tracking in a validated TMF system
- 🔄 Periodically review and update SOPs based on current regulatory updates
- 🤝 Clarify retention obligations in CRO, vendor, and site agreements
- 📁 Maintain retrieval logs to demonstrate audit readiness
For example, retaining data for stability testing protocols across regions often requires harmonizing timelines to avoid early data disposal that could impact market authorization.
Case Example: Global Trial Compliance
In a global cardiovascular trial, the sponsor adopted a 25-year minimum retention policy based on EMA requirements despite shorter timelines in other regions. They stored eTMF documents in a cloud-based, validated archive with regional access permissions. During an inspection by EMA, the sponsor provided rapid access to consent forms and audit trails, resulting in zero data integrity findings.
Retention-Related Regulatory Risks:
- ❌ Inadequate storage conditions for physical archives
- ❌ Missing or incomplete metadata in electronic systems
- ❌ No proof of SOP implementation or training
- ❌ Retention periods shorter than local or sponsor-mandated timelines
Mitigate these risks through training, periodic audits, and GMP documentation of archiving activities.
Conclusion: Retention Is a Regulatory Foundation
Understanding and adhering to data retention periods by region is vital to ensure GCP compliance, product approval, and audit readiness. With increasing regulatory scrutiny and globalization of trials, sponsors must define robust, harmonized retention strategies that reflect local and international expectations.
By incorporating clear SOPs, validated systems, and thorough documentation, you can future-proof your trial data and maintain the integrity required by regulators across the globe.